California Institute for Quantitative Biosciences

ERC Positions for Growth Supporting Defense and Space Mission Success

Retrieved on: 
Tuesday, November 9, 2021
Industry, Aerospace engineering, Atmosphere of Earth, Space Launch System, Government, U.S. Department of Defense Strategy for Operating in Cyberspace, Engineering, CEO, California, Growth, United, Research, Software, Capability, Atmosphere, LLC, Partnership, NASA, Doctor of Philosophy, Solution, California Institute for Quantitative Biosciences, ERC, Risk management

The company's leading-edge services enhance readiness, optimize performance, and help ensure mission success in the air, on the ground, and in space.

Key Points: 
  • The company's leading-edge services enhance readiness, optimize performance, and help ensure mission success in the air, on the ground, and in space.
  • "We understand that our defense and space industry customers operate in a dynamic environment, and we are positioning our organization to best meet their changing needs," said Ernie Wu, CEO of ERC.
  • Throughout its three-decade history, the ERC team has gained extensive experience in supporting a wide range of defense and space missions.
  • ERC is a leading provider of mission-critical engineering, technical and consulting services to the space and defense markets.

OpenEye Scientific Introduces Its Scientific Advisory Board

Retrieved on: 
Thursday, October 28, 2021
Massachusetts Institute of Technology, Method, Ligand, Biology, Research, Chemistry, Technology, Biophysics, Physics, University, Perelman School of Medicine at the University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Industry, University of Leeds, Massachusetts, DNA-binding protein, OpenEye Scientific Software, Kinetics, Computational biology, Drug discovery, School, Agrochemical, Princeton University Department of Chemistry, Weill Cornell Medicine, California Institute for Quantitative Biosciences, United States Air Force Scientific Advisory Board, Protein, CEO, Multimedia, Biochemistry, University of California, Davis, Program, Organic acid, Orion, Therapy, Associate, Department, University of California, San Francisco, Medical device, Pharmaceutical industry, Management

SANTA FE, N.M., Oct. 28, 2021 /PRNewswire/ --OpenEye Scientific, an industry leader in computational molecular design, has officially introduced its Scientific Advisory Board, which includes experts in the fields of biophysics and molecular modeling.

Key Points: 
  • SANTA FE, N.M., Oct. 28, 2021 /PRNewswire/ --OpenEye Scientific, an industry leader in computational molecular design, has officially introduced its Scientific Advisory Board, which includes experts in the fields of biophysics and molecular modeling.
  • The Scientific Advisory Board will provide guidance and support to OpenEye as it continues development of its methods and technologies and as it revolutionizes drug discovery with Orion, its cloud-native computational environment.
  • "OpenEye's Scientific Advisory Board is a great asset," said Anthony Nicholls, CEO of OpenEye Scientific.
  • Members of the OpenEye Scientific Advisory Board include:
    John Chodera, Ph.D.- Dr. Chodera is an Associate Member at Memorial Sloan Kettering Cancer Center.

Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors

Retrieved on: 
Thursday, October 28, 2021
Safety, TNK, European Medicines Agency, Organization, History, National Operating Committee on Standards for Athletic Equipment, Health, Multiple sclerosis, Trastuzumab, Amyotrophic lateral sclerosis, Therapy, California Institute for Quantitative Biosciences, Research, Cros, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, California Institute for Regenerative Medicine, EVP, Genetics, Physician, Biotechnology, Global health, Speranza, EMA, Genentech, Phrase, CEO, Rituximab, Nursing, CMO, Sale, CIRM, Board of directors, Orphan drug, Technology, University, Annual report, Neurodegeneration, Regenerative medicine, Patient, Computational biology, NASDAQ, FDA, MS, Growth hormone, National, Board, TPA, Pharmaceutical industry, Management

NEW YORK, Oct. 28, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to the company's Board of Directors.

Key Points: 
  • NEW YORK, Oct. 28, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to the company's Board of Directors.
  • "I am pleased to welcome Menghis to our Board of Directors," said Chaim Lebovits, Chief Executive Officer, Brainstorm Cell Therapeutics.
  • Mr. Abbhi commented, "It has been a real privilege to serve on Brainstorm's board and participate in the company's mission and strategy.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Biocom California Institute and California Life Sciences Release 2021 Life Sciences Workforce Trends Report for California

Retrieved on: 
Wednesday, October 27, 2021
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Research, Biotechnology, Workplace, Ecosystem, Industry, Innovation, Workforce, Twitter, Adoption, Public policy, Government, Communication, Churn, Senior, Learning, CLS, CEO, DE, Growth, COVID-19, Multimedia, Science, Solution, Health, CTE, Institute, University, Employment, Education, California Institute for Quantitative Biosciences, Creative industries, Ridesharing company, Management, Pharmaceutical industry, Medicine, Biocom California Institute, California Life Sciences (CLS), BIOCOM CALIFORNIA INSTITUTE, CALIFORNIA LIFE SCIENCES (CLS)

Biocom California Institute, a 501(c)(3) non-profit that supports life science innovation by strengthening the workforce and leaders of tomorrow, and California Life Sciences, a membership organization, advocating for the sector and its diverse innovation pipeline, announced their joint report, 2021 Life Sciences Workforce Trends .

Key Points: 
  • Biocom California Institute, a 501(c)(3) non-profit that supports life science innovation by strengthening the workforce and leaders of tomorrow, and California Life Sciences, a membership organization, advocating for the sector and its diverse innovation pipeline, announced their joint report, 2021 Life Sciences Workforce Trends .
  • Biocom California Institute is a 501(c)(3) that accelerates the growth of Californias life science ecosystem through innovative workforce development and life science education programs and strategies.
  • Biocom California Institute is an affiliate of Biocom California, the largest and most experienced advocate for Californias life science sector.
  • California Life Sciences (CLS) is the states most influential and impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline.

The Coretec Group Announces Promotions of Key Team Members

Retrieved on: 
Tuesday, October 26, 2021
Hardware, Alternative Energy, Alternative Vehicles, Fuels, Energy, Technology, Automotive, Environment, Semiconductor, Security, Engineering, Chemicals, Plastics, Audio, Video, Manufacturing, Science, California Institute of Technology, Engineering, Eli Lilly, University, Industry, Carbon, Applied physics, IP, Merck, Innovation, California, CO2, Electronics, Materials science, U.S. Securities and Exchange Commission, California Institute for Quantitative Biosciences, Risk, Physics, OTCQB, Semiconductor, Light-emitting diode, CEO, Growth, Environment, Quantum, Partnership, Master of Science, Health, Mechanical engineering, Publication, NSF, Silicon, SBIR, Entrepreneurship, Central Michigan University, Research

As the company continues to expand its IP and in turn its range of applications, the company is also growing and promoting its team.

Key Points: 
  • As the company continues to expand its IP and in turn its range of applications, the company is also growing and promoting its team.
  • Dr. Tokarz developed her science and business acumen in the pharmaceutical industry holding research chemistry and subsequent production roles for Merck and Eli Lilly.
  • Michelle and Ramez are key players in the growth of The Coretec Group.
  • The Coretec Group serves the global technology markets in energy, electronics, semiconductor, solar, health, environment, and security.

Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

Retrieved on: 
Wednesday, October 13, 2021
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Central nervous system, Lists of diseases, Transformation/transcription domain-associated protein, Director, Autism, California Institute for Quantitative Biosciences, Â, Brain, IPC, Medicine, California, Board of directors, University of Tokyo, Neurodegeneration, Pathology, University, Bacteria, Series, Irritability, Safety, Anxiety, Board, Therapy, Research, Axial, Drug discovery, Pharmaceutical industry, Management, Dietary supplement, AB-2004, Axial Therapeutics, AB-2004, AXIAL THERAPEUTICS

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing.

Key Points: 
  • Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing.
  • The additional financing builds upon Axials earlier Series A and Series B financing rounds, bringing total investment in the company to $91.5 million to date.
  • Proceeds from the Series C financing will be used to advance the clinical development of Axials lead candidate, AB-2004, a gut-restricted molecular therapy for irritability in children with autism.
  • Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases.

NeuroMetrix Announces Participation in the Center to Stream Healthcare In Place (C2SHIP) as an Industry Partner

Retrieved on: 
Tuesday, October 5, 2021
Cloud, Data science, California, Goal, Biomedical Research, Partnership, NSF, Chronic pain, Quell, Diagnosis, Pain management, Student, Patient, Division, UCRC, GLOBE, California Institute for Quantitative Biosciences, CEO, University, Company, Center, Pain, Peripheral neuropathy, Baylor College of Medicine, University of Southern California, Clinical research, Technology transfer, Baylor University, Nerve, Nasdaq, Industry, Lists of diseases, Pharmaceutical industry

WOBURN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner.

Key Points: 
  • WOBURN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner.
  • The initial four participating academic centers are the University of Arizona, Baylor College of Medicine, University of Southern California and the California Institute of Technology.
  • "We are pleased to welcome NeuroMetrix to C2SHIP as one of our industrial members.
  • The mission of the Center to Stream Healthcare In Place (C2SHIP) is to engage academic and industrial partners in joint efforts that develop healthcare technologies for in-place care and accelerate innovation through multi-specialty collaborations.

Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle

Retrieved on: 
Wednesday, September 15, 2021
Precision medicine, Investment, California, SAN, Health, Ecosystem, California Institute for Quantitative Biosciences, Doctor of Philosophy, Genome, Startup ecosystem, Genomics, Synthetic biology, YouTube, LinkedIn, Reproductive health, Industry, DNA, Therapy, Soil, NASDAQ, MD, Instagram, Twitter, Startup company, Agriculture, University of Oxford, Cancer, Video game, Antibiotics, Vaccine

SAN DIEGO, Sept. 15, 2021 /PRNewswire/ --Illumina, Inc.(NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator .

Key Points: 
  • SAN DIEGO, Sept. 15, 2021 /PRNewswire/ --Illumina, Inc.(NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator .
  • The global company creation engine, focused on partnering with entrepreneurs to build breakthrough genomics startups, invested in four companies for the 3rd funding cycle of Illumina Accelerator Cambridge, UK and three companies for the 13th funding cycle of Illumina Accelerator San Francisco Bay Area.
  • "The global reach of Illumina Accelerator is demonstrated by our investment in these seven diverse startups from six countries," said Amanda Cashin, PhD, co-founder and Global Head of Illumina For Startups.
  • Illumina for Startups initiatives include Illumina Accelerator, founded in 2014, and Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina, launching Fall 2021.

Public Invited to Join the Next NASA Virtual Getting to Know Goddard Session

Retrieved on: 
Tuesday, September 7, 2021

GREENBELT, Md., Sept. 7, 2021 /PRNewswire/ -- NASA 's Goddard Space Flight Center will host the latest Getting to Know Goddard session "Space Weather" on Thursday, September 9, 2021, from 1 to 2 p.m. EDT.

Key Points: 
  • GREENBELT, Md., Sept. 7, 2021 /PRNewswire/ -- NASA 's Goddard Space Flight Center will host the latest Getting to Know Goddard session "Space Weather" on Thursday, September 9, 2021, from 1 to 2 p.m. EDT.
  • This session will cover what we know about energetic particles, what we don't know and some plans for the future.
  • The Getting to Know Goddard speaker series was created to introduce the work being done at Goddard to the public.
  • If you would like to join our mailing list to receive notifications about events like Getting to Know Goddard, please join our mailing list at https://nvite.jsc.nasa.gov/RSVP/?id=8gkce .

Oerth Bio Announces Strategic Additions to Leadership Team

Retrieved on: 
Thursday, August 26, 2021
Technology, Science, Fitness & Nutrition, Agriculture, Natural Resources, Biotechnology, Health, Public Relations, Investor Relations, Other Science, Chemicals, Plastics, Food, Beverage, Marketing, Other Technology, Communications, Manufacturing, Retail, Environment, California Institute for Quantitative Biosciences, Population, Herbicide, Genome, University, Corporate development, Massachusetts Institute of Technology, Investment, University of California, Santa Cruz Silicon Valley Initiatives, Virus, Plant, Business, Agriculture, Nitrogen, Leadership, Fungus, Attune, Science, Pest control, Disease, Doctor of Philosophy, University of Massachusetts Amherst Department of Food Science, Marketing, Animal, Intellectual property, MBA, Indigo Agriculture, Head, Bio, Environment, Immunity, Pesticide, Liberty University, Communication, Taste, BS, Management, the Attune, Oerth Bio, THE ATTUNE, OERTH BIO

Oerth Bio is advancing its proprietary Attune platform to produce PROTAC molecules that protect, fine-tune, and biostimulate crops facing significant threats.

Key Points: 
  • Oerth Bio is advancing its proprietary Attune platform to produce PROTAC molecules that protect, fine-tune, and biostimulate crops facing significant threats.
  • We relish the challenge of rapidly translating this promising therapeutic modality into agriculture, said John Dombrosky, Chief Executive Officer of Oerth Bio.
  • Prior to joining Oerth Bio, he was Vice President of Commercial Strategy at Indigo Agriculture, Inc. where he led commercial strategy and operations.
  • Prior to joining Oerth Bio, she held various global leadership positions within Syngenta Seeds R&D, most recently Head of Learning & Transformation.